Clinical Trial Update: Olaparib in Combination With Vorinostat in Patients With Relapsed/Refractory and/or Metastatic Breast Cancer [Phase 1]

View source ↗

Summary

Phase 1 clinical trial update of olaparib in combination with vorinostat in patients with relapsed/refractory and/or metastatic breast cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Olaparib (Olaparib)
• Vorinostat (vorinostat)

Snippet

Sponsor: The Methodist Hospital Research Institute | Conditions: Breast Cancer Metastatic, Breast Cancer | Phase 1 | Status: ACTIVE_NOT_RECRUITING